Table 4.

Studies that have Investigated Immunotherapy in Patients with ACC

MoleculePhasePopulation (n)Prior systemic treatmentResults
Pembrolizomab 200 mg every 3 w (35 cycles)IΙ3928PFS=2.1, O.S=24.9 ORR (RECIST)=23%
Pembrolizomab 200 mg every 3 w (35 cycles)II1616SD at 27 w=36%, ORR(RECIST)=14%
Nivolumab 240 mg every 2 wII1010PFS=1.8, ORR=11%
Avelumab 10 mg/kg every 2 w (±mitotane)Ib5050PFS=2.6, OS=10.6, ORR=6%

ORR= objective response rates; PFS= progression-free survival; SD= stable disease; OS= overall survival

From: Current Issues in the Diagnosis and Management of Adrenocortical Carcinomas

Cover of Endotext
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Copyright © 2000-2024, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.